Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterisation of circulating microRNA-21 levels in patients with hypertrophic cardiomyopathy

19 Apr 2020

Abstract excerpt

AIM: To study the levels of circulating microRNA-21 in patients with hypertrophic cardiomyopathy (HCM) of different ages. MATERIALS AND METHODS: The study included 49 patients with HCM. The proportion of females was 55.1%, males 44.9%. The average age was 50 [32; 65] (from 19 to 86 years). The control group for microRNA-21 included 44 healthy individuals, respectively, matched by the age and sex with the studied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac Fibrosis and Remodeling
Share to Cardiomyopathy and Myosin Studies
Share to IL-33, ST2, and ILC Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32598698
DOI: 10.26442/00403660.2020.04.000272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterisation of circulating microRNA-21 levels in patients with hypertrophic cardiomyopathyPMID 32598698Read ↗

MicroRNAs in hypertrophic cardiomyopathy: pathogenesis, diagnosis, treatment potential and roles as clinical biomarkersSemantic proximity Read ↗

MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the ArtSemantic proximity Read ↗

A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathySemantic proximity Read ↗

Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic CardiomyopathySemantic proximity Read ↗

MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated CardiomyopathySemantic proximity Read ↗

Circulating MicroRNAs Identify Early Phenotypic Changes in Sarcomeric Hypertrophic Cardiomyopathy.Semantic proximity Read ↗

MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCMSemantic proximity Read ↗

Circulating miR-499a-5p Is a Potential Biomarker of MYH7-Associated Hypertrophic Cardiomyopathy.Semantic proximity Read ↗

Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy.Semantic proximity Read ↗

Circulating microRNAs as potential biomarkers of hypertrophic cardiomyopathy phenotypic expressionSemantic proximity Read ↗

Correlation of miR-146a-5p plasma levels and rs2910164 polymorphism with left ventricle outflow tract obstruction in hypertrophic cardiomyopathy.Semantic proximity Read ↗

MicroRNAs in the cardiovascular systemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.